Intraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized delivery.

Pandey, M; Wen, PX; Ning, GM; Xing, GJ; Wei, LM; Kumar, D; Mayuren, J; Candasamy, M; Gorain, B; Jain, N; Gupta, G; Dua, K

Intraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized delivery.

Pandey, M Wen, PX Ning, GM Xing, GJ Wei, LM Kumar, D Mayuren, J Candasamy, M Gorain, B Jain, N Gupta, G Dua, K

Permalink

Publisher:: Future Science Group
Publication Type:: Journal Article
Citation:: Nanomedicine (Lond), 2022, 17, (24), pp. 1871-1889
Issue Date:: 2022-10

Closed Access

	Filename	Description	Size
	20610720_10429118090005671.pdf		4.99 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Pandey, M
dc.contributor.author	Wen, PX
dc.contributor.author	Ning, GM
dc.contributor.author	Xing, GJ
dc.contributor.author	Wei, LM
dc.contributor.author	Kumar, D
dc.contributor.author	Mayuren, J
dc.contributor.author	Candasamy, M
dc.contributor.author	Gorain, B
dc.contributor.author	Jain, N
dc.contributor.author	Gupta, G
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2023-04-17T00:33:39Z
dc.date.available	2023-04-17T00:33:39Z
dc.date.issued	2022-10
dc.identifier.citation	Nanomedicine (Lond), 2022, 17, (24), pp. 1871-1889
dc.identifier.issn	1743-5889
dc.identifier.issn	1748-6963
dc.identifier.uri	http://hdl.handle.net/10453/169832
dc.description.abstract	Ductal carcinoma in situ describes the most commonly occurring, noninvasive malignant breast disease, which could be the leading factor in invasive breast cancer. Despite remarkable advancements in treatment options, poor specificity, low bioavailability and dose-induced toxicity of chemotherapy are the main constraint. A unique characteristic of nanocarriers may overcome these problems. Moreover, the intraductal route of administration serves as an alternative approach. The direct nanodrug delivery into mammary ducts results in the accumulation of anticancer agents at targeted tissue for a prolonged period with high permeability, significantly decreasing the tumor size and improving the survival rate. This review focuses mainly on the intraductal delivery of nanocarriers in treating ductal carcinoma in situ, together with potential clinical translational research.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Future Science Group
dc.relation.ispartof	Nanomedicine (Lond)
dc.relation.isbasedon	10.2217/nnm-2022-0234
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0306 Physical Chemistry (incl. Structural), 1004 Medical Biotechnology, 1007 Nanotechnology
dc.subject.classification	Nanoscience & Nanotechnology
dc.subject.mesh	Humans
dc.subject.mesh	Female
dc.subject.mesh	Carcinoma, Intraductal, Noninfiltrating
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Humans
dc.subject.mesh	Carcinoma, Intraductal, Noninfiltrating
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Female
dc.subject.mesh	Carcinoma, Intraductal, Noninfiltrating
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Antineoplastic Agents
dc.title	Intraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized delivery.
dc.type	Journal Article
utslib.citation.volume	17
utslib.location.activity	England
utslib.for	0306 Physical Chemistry (incl. Structural)
utslib.for	1004 Medical Biotechnology
utslib.for	1007 Nanotechnology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2023-04-17T00:33:37Z
pubs.issue	24
pubs.publication-status	Published
pubs.volume	17
utslib.citation.issue	24

Abstract:

Ductal carcinoma in situ describes the most commonly occurring, noninvasive malignant breast disease, which could be the leading factor in invasive breast cancer. Despite remarkable advancements in treatment options, poor specificity, low bioavailability and dose-induced toxicity of chemotherapy are the main constraint. A unique characteristic of nanocarriers may overcome these problems. Moreover, the intraductal route of administration serves as an alternative approach. The direct nanodrug delivery into mammary ducts results in the accumulation of anticancer agents at targeted tissue for a prolonged period with high permeability, significantly decreasing the tumor size and improving the survival rate. This review focuses mainly on the intraductal delivery of nanocarriers in treating ductal carcinoma in situ, together with potential clinical translational research.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/169832